03 January 2021 : Clinical Research
Co-Infection with Common Respiratory Pathogens and SARS-CoV-2 in Patients with COVID-19 Pneumonia and Laboratory Biochemistry Findings: A Retrospective Cross-Sectional Study of 78 Patients from a Single Center in China
Man-Ling Tang1ABCDEF, Yue-Qiu Li2BCDF, Xiang Chen1BCDF, Hui Lin1BCD, Zhong-Chun Jiang2BCD, Dai-Li Gu2BCD, Xun Chen2BCF, Cai-Xi Tang2ACDF, Zhi-Qin Xie2ABCDEFG*DOI: 10.12659/MSM.929783
Med Sci Monit 2021; 27:e929783
Table 1 Comparisons of clinical characteristics between co-infected and mono-infected COVID-19 patients with univariate analysis.
| Total | Monoinfection group | Coinfection group | P value | |
|---|---|---|---|---|
| 78 | 67 | 11 | – | |
| 0.887 | ||||
| Male | 41 (52.6%) | 35 (52.2%) | 6 (54.5%) | |
| Female | 37 (47.4%) | 32 (47.8%) | 5 (45.5%) | |
| 47.7±17.2 | 48.5±17.5 | 42.7±14.9 | 0.252 | |
| 0.832 | ||||
| ≤20 | 5 (6.4%) | 4 (6.0%) | 1 (9.1%) | |
| 21–40 | 24 (30.8%) | 20 (29.9%) | 4 (36.4%) | |
| 41–60 | 28 (35.9%) | 24 (35.8%) | 4 (36.4%) | |
| >60 | 21 (26.9%) | 19 (28.4%) | 2 (18.2%) | |
| 66 (84.6%) | 58 (86.6%) | 8 (72.7%) | 0.377 | |
| Fever | 56 (71.8%) | 47 (70.1%) | 9 (81.8%) | 0.425 |
| Cough | 62 (79.5%) | 53 (79.1%) | 9 (81.8%) | 0.836 |
| Expectoration | 39 (50%) | 34 (50.7%) | 5 (45.5%) | 0.745 |
| Fatigue | 36 (46.2%) | 28 (41.8%) | 8 (72.7%) | 0.056 |
| Shortness of breath | 25 (32.1%) | 23 (34.3%) | 2 (18.2%) | 0.288 |
| Chest tightness | 7 (9.0%) | 6 (9.0%) | 1 (9.1%) | 0.988 |
| Chest pain | 3 (3.8%) | 2 (3.0%) | 1 (9.1%) | 0.370 |
| Diarrhea | 13 (16.7%) | 12 (17.9%) | 1 (9.1%) | 0.467 |
| Muscular soreness | 18 (23.1%) | 16 (23.9%) | 2 (18.2%) | 0.678 |
| Body temperature (°C) | 37.3 (36.7–38.5) | 37.4 (36.7–38.5) | 37.3 (36.8–39.1) | 0.714 |
| Blood oxygen saturation level (%) | 98.0 (96.0–98.0) | 98.0 (96.0–98.0) | 98.0 (95.5–98.0) | 0.749 |
| Pulse rate (beats/min) | 88.2±10.8 | 87.6±11.1 | 92.0±8.3 | 0.588 |
| Respiratory rate (breaths/min) | 20 (20–20) | 20 (20–20) | 20 (20–25) | 0.921 |
| 78 (100.0%) | 67 (100.0%) | 11 (100.0%) | 0.467 | |
| Ground-glass opacity (GGO) | 65 (83.3%) | 55 (82.1%) | 10 (90.9%) | |
| No obvious abnormalities | 13 (16.7%) | 12 (17.9%) | 1 (9.1%) | |
| Diabetes | 8 (10.3%) | 7 (10.4%) | 1 (9.1%) | 0.891 |
| Cardiovascular and cerebrovascular diseases | 19 (24.4%) | 17 (25.4%) | 2 (18.2%) | 0.607 |
| Chronic obstructive pulmonary disease (COPD) | 6 (7.7%) | 6 (9.0%) | 0 (0.0%) | 0.586 |
| Chronic liver disease | 6 (7.7%) | 5 (7.5%) | 1 (9.1%) | 1.000 |
| 0.555 | ||||
| Mildly group | 8 (10.3%) | 6 (9.0%) | 2 (18.2%) | |
| Moderately group | 59 (75.6%) | 52 (77.6%) | 7 (63.6%) | |
| Severely/critically group | 11 (14.1%) | 9 (13.4%) | 2 (18.2%) | |
| 4.0 (2.0–6.0) | 4.0 (2.8–7.0) | 3.0 (1.5–4.0) | 0.173 | |
| 13 (11–20) | 14 (10–21) | 13 (12–14) | 0.205 | |
| Quantitative variables are expressed as median (interquartile range) or mean±standard deviation; categorical variables are expressed as frequencies (percentages);CT – computerized tomography. | ||||